- Home
- QNCX vs ASRT Comparison
QNCX vs ASRT Comparison
Compare QNCX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ASRT
- Stock Information
- Founded
- QNCX 2012
- ASRT 1995
- Country
- QNCX United States
- ASRT United States
- Employees
- QNCX N/A
- ASRT N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- ASRT Health Care
- Exchange
- QNCX Nasdaq
- ASRT Nasdaq
- Market Cap
- QNCX 47.7M
- ASRT 57.9M
- IPO Year
- QNCX 2019
- ASRT 1997
- Fundamental
- Price
- QNCX $1.64
- ASRT $0.63
- Analyst Decision
- QNCX Strong Buy
- ASRT Strong Buy
- Analyst Count
- QNCX 5
- ASRT 2
- Target Price
- QNCX $8.00
- ASRT $3.25
- AVG Volume (30 Days)
- QNCX 353.3K
- ASRT 248.2K
- Earning Date
- QNCX 08-12-2025
- ASRT 08-06-2025
- Dividend Yield
- QNCX N/A
- ASRT N/A
- EPS Growth
- QNCX N/A
- ASRT N/A
- EPS
- QNCX N/A
- ASRT N/A
- Revenue
- QNCX N/A
- ASRT $119,001,000.00
- Revenue This Year
- QNCX N/A
- ASRT N/A
- Revenue Next Year
- QNCX N/A
- ASRT $11.91
- P/E Ratio
- QNCX N/A
- ASRT N/A
- Revenue Growth
- QNCX N/A
- ASRT N/A
- 52 Week Low
- QNCX $0.51
- ASRT $0.51
- 52 Week High
- QNCX $2.45
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- QNCX 64.95
- ASRT 53.64
- Support Level
- QNCX $1.48
- ASRT $0.63
- Resistance Level
- QNCX $1.68
- ASRT $0.68
- Average True Range (ATR)
- QNCX 0.14
- ASRT 0.03
- MACD
- QNCX 0.02
- ASRT 0.00
- Stochastic Oscillator
- QNCX 85.71
- ASRT 74.71
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.